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BRAIN, RARE NEUROLOGICAL DISEASES AND
EUROPEAN HEALTH CARE SYSTEMS
Bowis J
OBE, UK
“We are here to build a partnership for rare diseases and for the
children, in particular, who live with them,” and the European
Commission should be applauded for its willingness to listen
and respond.
A rare disease, by definition, does not affect many people.
The paradox is that, as a group, rare diseases are common;
there are about 6,000 of them. In the UK, it is estimated that
3.5 million people live with a rare disease. In Europe it is
approximately 33 million. Some 75% of rare diseases affect
children, and 30% of such children die before their fifth
birthday (http://www.raredisease.org.uk/index.html). Many
of these rare disorders are neurological, it is important for
us to recognize that neurological disorders are not exclu-
sively linked to longevity, and that they affect large
numbers of children.
For children with neurological disorders we need
research into the various causes and the impact of these
conditions, as well as potential treatments. This is
expensive. It has never been a more difficult time to
promote investment in health as a priority for govern-
ments, and yet never has there been a more important
time to do so. The number of patients affected by rare
neurological diseases during childhood makes it clear
that these conditions should figure in the mainstream
economic argument. If governments and directorates,
and international and national agencies, and health
services do nothing, the cost of such inaction will be
immense. If we invest in research, prevention, treatment
and care now, then the future economic benefits can
also be immense for individuals, families and econo-
mists. We will really personalised treatment and cure
patients at the right moment with the adequate amount
of drug. For all these reasons, we have to educate the
public about these rare disorders and recruit them to the
battle to persuade governments and international agen-
cies that child brain research deserves a higher priority
and greater investment.
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Perinatal asphyxia
Oxygen deficit at delivery can lead to severe hypoxic ischemic
organ damage in newborns followed by a fatal outcome or
severe life-long pathologies. The severe insults often cause
neurodegenerative diseases, mental retardation and epilepsies.
The mild insults lead to so-called “minimal brain-damage
disorders” such as attention deficits and hyperactivity, but can
also be associated with the development of schizophrenia and
life-long functional psychotic syndromes. Asphyxia followed
by re-oxygenation can potentially lead to development of
several neurodegenerative pathologies, type 2 diabetes mellitus
and cancer.
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Birth asphyxia as the major pathology amongst perinatal
complications
According to the statistical data collected in years
2000–2002 by the Global Burden of Disease Study,
worldwide 56 million deaths occur every year, from that
10.5 million, i.e. 20% represent children aged below
5 years. In this group, the leading cause of death is
perinatal complications. Worldwide epidemiological data
demonstrate the perinatal morbidity comprising 60% of
the child death. These facts reflect extensive field-
related problems in current healthcare and massive
deficits in both targeted prevention of perinatal compli-
cations and effective treatments during early postnatal
period.
Particularly alarming statistical data are currently deliv-
ered by developing countries with large populations
(Fig. 1).
Ethical and socio-economical impacts of educational
measures in prevention of birth asphyxia
Current limited perinatal and postnatal diagnostics cause
long-term consequences in a society, which can include a
spectrum of negative aspects. From a social and ethical
point of view, innovative technologies for an early/
predictive diagnostics and individualised treatment should
be applied in all routine medical services. From an
economic point of view, emphasis should be put into the
costs effectiveness to promote advanced healthcare with
appropriate budgets for targeted prevention applied before
pathologies manifest.
What are the potential measures that can be applied
already now? One example of the high impact of
educational measures to improve the healthcare system
is given in Fig. 2.
The prevalence of birth asphyxia registered for children
born to educated mothers is several times lower compared
with those born to uneducated/illiterate mothers. It is
evident that strong restrictions in the amount of education
lead to dramatic deficits and costs that are essentially then
felt in other branches of the system, including a conse-
quently chaotic healthcare in the society. When the whole
spectrum of asphyxia-related pathologies is considered such
as type 2 diabetes, neurodegenerative diseases and cancer,
the consequent costs increase dramatically for treatment of
manifesting pathologies. Therefore, new guidelines are
essential to regulate the field in favour of educational
measures, personalised treatment approaches before mani-
festing pathologies, particular emphases on primary pre-
vention, innovative reimbursement programmes introduced
by policy-makers.
Expression profiling by “Gene Hunting”- technology
discovered functional groups of genes involved in the
pathophysiology of perinatal asphyxia
This strategy has been chosen to identify functional groups
of genes, differentially regulated in the brain under the
severe birth asphyxia versus normoxia. The transcription
Fig. 1. The prevalence of birth asphyxia as documented by a series of
population studies: a corresponding number of cases has been























































Fig 2. Ratio of newborns with asphyxic deficits born to uneducated/
illiterated versus educated/literated mothers. Data taken from [2]
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profiling revealed the following functional groups of genes
affected by the asphyxia:
– synthesis of signaling molecules (such as nitric-oxide)
and heat-shock proteins
– nuclear and DNA-binding factors




– several metabolic pathways (e.g. nucleic acid, lipid
metabolism)
– redox-control and free-radical production
– proto-oncogenes.
Blood biomarker-candidates specific for asphyxia related
complications
Blood tests is a highly attractive approach for performing non-
invasive examinations to accurately diagnose a severity grade
of birth asphyxia and to predict/prognose individual predis-
positions to or a progression of secondary complications in
asphyxia affected newborns. A blood–brain barrier perme-
ability discovered in hypoxic-ischemic excephalopathy well
explains potential correlations in pathology specific molecular
profiles between brain and blood, justifying the high
prognostic value of non-invasive blood examinations.
Outlook
The task of individual prediction, targeted prevention and
personalized treatments before a manifestation of the life-long
chronic pathologies usually developed by newborns with
asphyxic deficits, should be given the extraordinary priority in
neonatology and paediatrics. In the clinical setting, after
resuscitation of an infant with birth asphyxia, the emphasis is
on supportive therapy. Several interventions have been
proposed to attenuate secondary neuronal injuries elicited by
asphyxia. Hypothermia has been pointed out to be an effective
intervention against the secondary neuronal injury, elicited by
the birth asphyxia. Applied immediately after birth asphyxia,
hypothermia generally lowers metabolic rates, and diminishes
the glutamate levels in brain. Although promising, the clinical
efficacy of hypothermia has not been fully demonstrated. It is
evident that new approaches are warranted.
In the context of neuro- and anticancer-protection, several
sentinel proteins have been described to protect the integrity
of the genome (e.g. PARP-1; XRCC1; DNA ligase IIIα; DNA
polymerase β, ERCC2, DNA-dependent protein kinases).
They act by eliciting metabolic cascades leading to (i)
activation of cell survival and neurotrophic pathways; (ii)
early and delayed programmed cell death, and (iii)
promotion of cell proliferation, differentiation, neurito-
genesis and synaptogenesis. It is proposed that sentinel
proteins can be used as markers for characterising long-
term effects of perinatal asphyxia, and as targets for
novel therapeutic development and innovative strategies
for neonatal care [3].
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APPLICATION OF PROTEOMICS FOR THE IDEN-
TIFICATION OF PROTEINS WITH DIAGNOSTIC
AND THERAPEUTIC IMPORTANCE IN TURNER
SYNDROME PATIENTS
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GT1
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Turner syndrome (TS) is the most common chromosomal
abnormality in females, affecting 1: 2500 live female births and
is the result of absence or structural abnormality of one X
chromosome. In the present study proteomic techniques were
applied in order to identify proteins differentially expressed in
the peripheral blood of TS patients as compared to normal
females. Plasma samples from 12 girls with TS and a 45, XO
karyotype aged from 5 to 7 years and 12 matched for age
chromosomally normal controls were analyzed by two-
dimensional gel electrophoresis (2D-E) followed by matrix
assisted laser desorption ionization time-of-flight mass spec-
trometry (MALDI-TOF-MS). Through densitometric analysis,
gel comparison of Turner and normal cases revealed significant
differences in protein expression. Eleven proteins; ZA2G,
A2GL, OTUB2, FETUA, KNG1, VTDB, APOH, A2MG,
FIBA, FIBB and CLUS were up-regulated in Turner syndrome
patients whilst four, ACTB, ACTG, HPT and APOE, were
found to be down- regulated. Amongst the proteins of interest, a
brain specific cell adhesion molecule neurogelin 3 (NL3) was
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noted to adhere differential expression in all samples included
in the study. Protein levels of NL3, KNG1, FETUA and APOE
were further evaluated by immmunoblot analysis. Detection of
differentially expressed molecules could improve our under-
standing over the unique pathophysiology of the syndrome and
allow better management of TS patients.
A NON-INVASIVE FETAL RHD GENOTYPING TEST
TO TARGETANTENATAL ANTI-D PROPHYLAXIS
Tounta G1, Kolialexi A1, Vrettou C1, Papantoniou N2,
Tsangaris G3, Antsaklis A1, Kanavakis E1, Mavrou A1
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Objective: To design a protocol for non-invasive prenatal
diagnosis (NIPD) of foetal Rhesus D (RhD) status.
Methods: 112 single lymphocytes were used to test the
efficiency of the assay. The protocol was validated using
blood samples from 84 RhD-negative pregnant women at
7–24 weeks of gestation.
Isolated cell free DNA (cfDNA) was enzymatically
digested using AciI and analyzed by a multiplex PCR that
allowed for the simultaneous amplification of RHD exons 7
and 10, SRY, RASFF1A and ACTB. Amplification of these
loci detected fetal RhD status and gender, confirmed the
presence of cfDNA and allowed for assessment of digestion
efficiency.
Results: On the one genome equivalent level, the efficiency of
the protocol was ≥94.6% for each locus amplified. Conclusive
results from the 1st set of PCRs were obtained for 79 cases
(94%) with one false-positive. In 14 samples with negative
RHD and SRY results, the presence of cffDNAwas confirmed
by amplification of RASSF1A. In 5 cases analysis was
repeated and all were accurately diagnosed.
Conclusion: After exclusion of the case with the suspected
RHD variant allele, 82/83 samples were accurately diag-
nosed, with a 3.3% false positive rate, giving a specificity
96.7% and 100% sensitivity.
EVALUATION OF NEURODEGENERATIVE
DISORDERS: THE SEARCH FOR BIOMARKERS
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1Leibniz-Institut für Molekulare Pharmakologie, Berlin-
Buch, Germany
2Laboratoire de Biochimie, INSERM ERI12, Centre Hos-
pitalier Universitaire d’Amiens, France
3Pasteur Institute, Paris, France
To characterize the progress of neurodegenerative diseases,
specific biomarkers are needed. The cerebrospinal fluid (CSF)
directly contacts the CNS and, hence, represents a stable
reporter compartment for the physiological, pathological and
pharmacological status of the degenerative brain. The CSF is
characterized by a relatively low number of proteins and well
suitable for proteomic analyses. The analytics of the potentially
more predictive low abundant proteins is complicated by high
abundant proteins, such as albumins or globulins, representing
more than 75% of the protein content of the CSF. Therefore, a
major problem of CSF proteomics is depletion of the high
concentration proteins. We report about our methodical efforts
to deplete the major proteins using CSF of different species.
Further, we analysed the CSF of a dog model for the
neurodegenerative lysosomal storage diseases mucopolysac-
chrosidosis III B (Sanfilippo syndrome type B) and mucopo-
lysacchrosidosis I (Hurler syndrome). Alterations in the
protein pattern, due to the disorders compared to the healthy
control, will be discussed to identify candidate biomarkers.
Then, clinical studies are required to investigate the transfer-
ability of the candidates to the human disease, and to validate
them as surrogate markers for MPSI and MPSIIIB.
UNDERSTANDING PATHOGENESIS:
FUNDAMENTAL INSIGHTS AND NEW THERAPEU-
TIC OPPORTUNITIES
Platt F
University of Oxford, UK
Lysosomal storage disorders occur at a collective frequency
of 1:5000 live births and are the commonest cause of
paediatric neurodegenerative disease.
Over 50 individual inherited monogenic disorders are
known that result from mutations in genes that play a role
in multiple aspects of lysosomal function.
The lysosome is the major site of macromolecule degrada-
tion/recycling within cells and when lysosomal function is
impaired molecules build up over time leading to “storage”.
The majority of these diseases involve pathology in the
brain and are currently without effective therapy.
Despite their simple genetic cause, the gene defect triggers
a remarkably complex set of down stream changes within
cells/organs/tissues that is termed a “pathogenic cascade”.
This typically culminates in severe neurological impairment
and visceral manifestations. It is interesting to note that
aspects of the pathogenic cascade are convergent between
lysosomal disorders and more common neurodegenerative
diseases.
We are currently in an era of research that is helping tease
apart the pathogenic cascade. The aim is to better
understand the disease process and identify biomarkers
and therapeutic intervention points for clinical translation.
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A particularly exciting aspect of this research is it may
identify clinical intervention points that could be treated
with currently available/approved drugs speeding up the
translational process. Due to the intrinsic heterogeneity of
these diseases personalised medicine will be required to
maximise clinical benefit.
TREASURING EXCEPTIONS: GOING FROM THE
PERSONAL TO THE FUTURE FOR ALL
Cox TM
Department of Medicine, University of Cambridge, UK
Fully completed in 2003, the lexicon of the human genome
stands at an epoch in medical research. This unprecedented
collaboration has brought innovative sequencing technolo-
gies and bioinformatic analysis to bear on intractable
problems in human genetics—not least of which has been
the discovery and characterization of hitherto unknown
disease-related genes.
Today, the structure of about 6,000 genes implicated in human
diseases has been elucidated; this includes many that cause
rare disorders. Such rare (‘orphan’ or even ‘ultra-orphan’)
conditions have long been known, but it is only now that they
can be annotated and characterized—and understood at the
molecular level. Moreover, in these times of relative affluence,
even striking scientific discoveries have been accompanied by
a societal revolution in which there is a collective desire to
understand the burden that rare disabilities represent to those
affected, as well as their immediate families.
With a rational perception of hereditary illness through
‘personalised genetic health’ has come the realization that
disease not only places a physical burden on society but an
imperative to assume the moral burden of responsibility for its
relief. The view of the diseased person as a broken machine,
with damaged parts, or even the whole, to be replaced (or, in
the case of some hereditary diseases, to be disposed of), is
outmoded. In this respect, the Darwinian view is both rational
and philanthropic: as Archibald Garrod showed, much illness
is the product of interactions between the individual and an
environment to which they are uniquely maladapted at a
particular time. The constitutional factors that come together
in the individual patient are the result of selective or neutral
factors introduced over millennia persist as complex determi-
nants of the existence of our species.
We are at the zenith of a golden age in which discoveries in
biology are being rapidly translated into improved medicines
and, even with the most intractable diseases such as those that
injure the brains of infants and children, therapeutic avenues are
opening up. Advances in cellular and molecular biology allow
us to have a comprehensive understanding of causation—but
they also provide the basis for our search for cures. Challenges
remain however—and ensuring that therapeutic quantities of
corrective medicines reach the injured brain is a hurdle that
merits intensive effort.
Here I discuss exceptional diseases as a paradigm for
discovery and as an unusual pathway in basic and applied
research. The conflation of orphan drug legislation and the
emerging power and commitment of patient organisations can
synergise to advance basic research and therapeutic develop-
ment in ultra-orphan diseases. In many instances gene transfer
and the emerging stem-cell techniques offer more immediate
promise of definitive correction of otherwise devastating
disorders, such as those which affect the brain; but their
therapeutic development and clinical application is beset with
regulatory difficulties and lack of political commitment.
Overcoming these impediments is mandatory for realizing the
value of our scientific investment- already it offers potential for
the relief of rare diseases that affect the brain of the young and
vulnerable. But this call has another critical dimension, and one
founded on a longstanding and unassailable principle of medical
science—that understanding rare inherited diseases provides
unique insights into the therapy of more common ones. There
aremany rare and disabling diseases: as a group not only do they
constitute an unquantifiable individual personal burden to
patients and their families, but they are prevalent. Moreover, as
a consequence of the natural genetic variation that maintains our
species, rare inherited diseases are a treasury for discovery and
biological progress. If we are to reduce their personal burden, we
must invest in research to understand their secrets and at the
same time invest directly to improve our future.
PATIENT-CENTRIC THERAPY AT THE RIGHT
MOMENT: CHALLENGES AND OPPORTUNITIES
IN THE DEVELOPMENT OF TREATMENTS
FOR CHILDREN WITH RARE NEUROLOGICAL
DISORDERS
Barton NW
Shire Human Genetic Therapies, Cambridge, MA, USA
The development of effective therapies for children with
inherited neurological diseases is a well recognized need
given the cumulative public health impact of these
disorders. Collaboration of multiple stakeholders including
academic scientists and physician investigators, patient
advocacy organizations, funding authorities and regulatory
bodies is required in order to make substantive progress
toward this goal. Selection of a disease target with a clear
therapeutic approach and committed investment by
concerned parties are key steps early in the process.
Demonstration of the potential benefits of a proposed
therapy in a relevant animal model is typically required to
attract a suitable biopharmaceutical partner who will have
the resources to advance the project further in development.
From a biopharmaceutical perspective, there are several
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unique challenges inherent in the development of personalized
medicines particularly for children with rare brain diseases.
Frequently the natural history of these diseases is poorly
understood and few patients are available for clinical study. To
further compound matters, correlations between the genetic
defect and the clinical features of the disease are often not
clear. An additional, frequently encountered limitation is the
small number of experts with deep clinical knowledge of the
illness of interest. Once the decision has been taken to advance
a compound with a supporting toxicology package into
clinical development, one must interact with regulatory bodies
that may be unfamiliar with the illness and what body of
evidence constitutes proof of benefit. These challenges are
often amplified by the lack of accepted clinical endpoints and
known biomarkers that inform dose selection. Given the
limited number of affected children who can participate in
clinical studies of rare neurodegenerative disorders, late
stage clinical trials must be executed on a global scale in
order to complete trial enrollment in a timely manner.
Clearly to succeed in the face of these risks and
challenges, substantial investment is required by all
parties: governmental authorities, advocacy groups and
industry. Given all of this complexity, what is the
opportunity? Success responds to huge unmet human
need and provides benefits to all.
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Introduction: Tourette syndrome (TS) is a childhood-onset
neuropsychiatric disorder characterized by multiple motor
and vocal tics and high co-morbidity rates with obsessive
compulsive disorder (OCD), attention deficit and hyperac-
tivity disorder (ADHD) (Swain et al., 2007). Detracting
further from the quality of life of affected individuals, TS
patients show deficits in procedural learning and have an
increased risk for depression and anxiety (Marsh, 2004).
The etiology and the pathophysiology of TS remain poorly
understood. It is currently thought that environmental and
genetic factors interact in order to lead to the onset of
symptoms. However, the exact role and the level of
contribution of each of these factors have not been yet
elucidated (State, 2011).
Among environmental factors, the possible involvement of
Group A Streptococcus (GAS) infection has been proposed,
mainly following the description of a rare group of TS
patients in whom tics and behavioural features fluctuate in
association with variations in the immunological response
to GAS [the so-called Paediatric Autoimmune Neuropsy-
chiatric Disorders Associated with Streptococcal infection
(PANDAS)] (Sweedo et al. 1998). Nevertheless, widely
accepted consensus-based criteria for the definition of
PANDAS are currently lacking.
Irrespective of the controversy concerning the concept of
PANDAS, preliminary but consistent data support the
presence of abnormalities of immune regulation in children
with TS (Kawikova et al. 2007). These alterations suggest
that environmental factors, among which GAS infections,
active on the immune system could modify the course of
severity of tics and associated symptoms in TS.
Aims: To evaluate the relationship between diagnosis and
clinical course of Tourette syndrome (TS) and exposure to
Group A Streptococcus (GAS).
Methods: GAS pharyngeal infections, anti-streptococcal
antibody response and expression of anti-basal ganglia
antibodies (ABGA) were compared between 168 TS
patients (mean ± SD age, 10 years 2 months±31 months)
and 177 control patients with epileptic or sleep disorders
(mean ± SD age, 9 years, 8 months±34 months), recruited
in four Italian tertiary referral outpatient services. One-
hundred-and-forty-four TS patients were followed up at 3-
monthly intervals for a mean of 3.3 visits/patient; exacer-
bations of tics, obsessive-compulsive symptoms and symp-
toms related to attention deficit/hyperactivity disorder,
depression and anxiety were defined by a bootstrap
procedure using validated rating scales. We assessed the
effect of new GAS infections and new ABGA identification
upon the risk of exacerbations using logistic regression
analysis. Odds ratio (OR) were computed on each type of
exacerbation adjusted for age, inter-visit interval, and
medication changes. All statistical analyses were performed
using statistical software package (Stata 11).
Results: When analyzed cross-sectionally, patients with TS
exhibited, compared to controls, a higher frequency of GAS
throat infection (7.7% vs. 1.7%; p=0.009), pathological
anti-streptolysin O (ASO) titers (57.7% vs. 33.9%; p<
0.0001), and ABGA (25.3% vs. 8.2%; p<0.0001). The
prospective study showed that ASO titers were persistently
S100 EPMA Journal (2011) 2 (Suppl 1):S95–S102
elevated in 57% of TS patients; however, new GAS
infections or newly identified ABGA did not significantly
predict the occurrence of either type of exacerbations of
obsessive-compulsive, ADHD, depressive or anxiety symp-
toms (table 1).
Interpretation: TS patients might be more prone to GAS
infections and develop stronger antibody responses to GAS,
probably as a result of underlying immune dysregulation.
At the same time, new GAS infections are unlikely to exert,
years after the onset, a relevant effect upon the severity of
neuropsychiatric symptoms.
COMPARATIVE STUDY OFALLELE FREQUENCIES
OF PAI-1, MTHFR, FV, FI AND GPIIIA GENE
POLYMORPHISMS IN CHILDREN WITH
HENOCH–SCHÖNLEIN PURPURA, SCHAMBERG
DISEASE AND HEALTHY CHILDREN
Shirinbekova NV, Voronina EV, Voitovich AN, Larionova VI
St. Petersburg State Pediatric Medical Academy, St. Petersburg,
Russia
Objectives: Comparative analysis of alleles and genotypes
distribution of plasminogen activator inhibitor 1 (PAI-1) -
675 4G/5G insertion-deletion polymorphism, methylene-
tetrahydrofolate reductase (MTHFR) -677C/T polymor-
phism, blood coagulation factor V (FV) 1691G/A
polymorphism, blood coagulation factor I (FI) -455G/A
polymorphism and platelet GpIIb/IIIa Pl A1A2 polymor-
phism in (1) children with Henoch–Schönlein purpura
(HSP), (2) in children with Schamberg Disease (SD) and
(3) in healthy children.
Patients and methods: HSP group consisted of 40 patients
(20 boys and 20 girls), SD-group consisted of 30 patients
(18 boys and 12 girls). Control group was composed of 46
apparently healthy children (22 boys and 24 girls). PAI-1-
675 4G/5G insertion-deletion polymorphism was analysed
by PCR method, MTHFR 677C/T, FV 1691G/A, FI -455G/
A and GpIIIa Pl A1A2 polymorphisms were analysed by
PCR-RFLP method. Statistical significance of differences
between groups was assessed using χ2 tests.
Results: There was no statistically significant (p>0.05)
difference in allele and genotype distribution of analysed
polymorphisms between HSP group, SD group and control
group. The genotype distribution was in accordance with
Hardy-Weinberg equilibrium for all variants. Genotype 5G/
5G PAI-1-675 wasn’t found in SD group. Genotype PlA2A2
GpIIIa wasn’t found in HSP and control groups. 1691A
allele of the FV gene wasn’t found in any group (all
children has “normal” GG genotype FV 1691).
Conclusion: In this study we did not find PAI-1-675 5G/5G
genotype in children with SD and there was no A -allele FV
1691G/A in any of studied groups. Genotype PlA2A2
GpIIIa was found neither in HSP, nor in control groups.
THE PERSONALIZED APPROACH TO DRUG DOS-
ING OF VALPROIC ACID AT WOMEN WITH
EPILEPSY, WHO ARE CARRIERS OF MUTATIONS
OF FOLATE CYCLE GENES
Dmitrenko D, Pilugina M, Shnayder N
Krasnoyarsk State Medical University named after Prof. V.F.
Vojno-Jasenetsky, Krasnoyarsk, Russia
The importance of the personalized approach to valproic
acid dosing at childbearing age women with epilepsy is
determined by increased risk of developing secondary
disorders of folate cycle and consequence of impaired
fertility function. This is particularly important for patients
who are carriers of certain gene polymorphisms of folate
cycle: for MTHFR gene—polymorphic variants c.665 C>T
(Ala222Val) and c.1286 A>C (Glu429Ala), for MTR gene—
polymorphism c.2756 A>G (Asp919Gly), and for MTRR
gene—c.66 polymorphismA>G (Ile22Met). The combination
of homozygous variant carriers of c.665 polymorphism C>T
(Ala222Val) (T/T) and homozygous variant polymorphism
c.1286 A>C (Glu429Ala) (A/A) of MTHFR gene leads to
significant reduction of folic acid in blood serum. In
addition the administration of anti-epileptic drugs (VPA
aggravates epilepsy) may lead to adverse drug events
(ADE) in form of impaired fertility (menstrual disorders,
miscarriage, increased risk of congenital malformation
of neural tube and chromosomal abnormalities in a child
despite normal karyotype of parents). These ADE may
have long-term consequences, even in the case of
administration of sub-therapeutic doses of VPA.
The risk of ADE increases by homozygous variant
polymorphism of MTR (G/G) and/or heterozygous variant
(A/G). The influence of this polymorphism on potentially
impaired fertility can be compounded by increased homo-
cysteine levels in carriers of MTHFR-related polymor-
phisms, even without additional supplementation of VPA.
There are also high impacts of the prevalent heterozy-
gous variant gene polymorphism in MTR (A/G) in the
population. At least 3 months before a planned pregnan-
cy and during the 1st trimester of it, an individualised
diet by enrichment of folic acid and vitamin B12 is
proposed for women, who are carriers of homozygous
and heterozygous MTR polymorphisms—c.2756 A>G
(Asp919Gly), especially when combined with MTHFR
polymorphisms—c.665 C>T (Ala222Val) and/or c.1286
A>C (Glu429Ala).
An impaired fertility is ten-time more frequent in women
with epilepsy under long-term VPA administration, who are
carriers of MTHFR or/and MTR and CYP2C9*2 and
CYP2C9*3 polymorphisms. Detection of these polymor-
phisms among women with epilepsy is clinically relevant,
since they require initial selection of individual low-dose
VPA medicamentation. In such cases the standard drug-
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dosages can lead to excessive accumulation of VPA in
serum and to extension of its metabolism in the liver
resulting in lower quality of life of young women by fertile
dysfunction. “Down-stream” complications can be further
expected such as a social and family maladjustment,
development of anxiety-depressive syndrome, disintegra-
tion of family.
DRUGS MAY CONTRIBUTE TO THE APPEAR-
ANCE OF ORAL-FACIAL CLEFTS IN NEWBORNS
Velickova N, Gacova M, Kamcev N, Angelovska B,
Dimova C
Faculty of medical science, University “Goce Delcev”—
Stip, Macedonia
Introduction: A cleft is a gap in a body structure that results
from incomplete closing of a specific structure during
development. Clefts that occur in the lip and palate (roof of
the mouth) are called oral-facial clefts. These defects occur
very early during fetal development. Cleft lips and palates
may be caused by a combination of genetic and environ-
mental factors.
The aim of this study was to evaluate potential risks factors
in children hospitalized in the faculty hospital of Stip for
effective preventive measures reducing an appearance of
oral-facial clefts in newborns.
Material and methods: Oral-facial clefts were diag-
nosed by physical exam after delivery. Potential risks
factors and drug exposure of mothers during pregnancy
were analyzed.
Results: The results indicated that during past 10 year
there was an increasing tendency in the incidence rate of
oral-facial clefts in newborns. Further, the oral-facial
defects were accompanied by other complications such
as feeding difficulties, frequent ear infections and hearing
loss.
Conclusion: Maternal drug abuse (amoxicillin, phenytoin,
oxprenolol, and thiethylperazine taken during the second
and third month of pregnancy), smoking, and pesticide
exposure were registered as the statistically significant risk
factors for oral-facial defects in newborns.
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